Communiqués Vertex Pharmaceuticals Incorporated

Actions

VRTX

US92532F1003

Produits pharmaceutiques

Temps réel estimé Cboe BZX 20:58:44 07/10/2026			Varia. 5j.	Varia. 1 janv.
506,80 ^USD	+0,89 %		-3,00 %	+11,86 %

13:52	Transcript : Vertex Pharmaceuticals Incorporated Presents at Bank of America Global Healthcare Conference 2026, Sep-23-2026 09:05 AM
28/09	Vertex Pharmaceuticals Incorporated : UBS reste à l'achat	ZM

Communiqués

22/09	Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial	BU
15/09	Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain	BU
01/09	Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team	BU
26/08	Vertex to Participate in Upcoming September Investor Conferences	BU
05/08	Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending JUNE 30, 2026 (Form 10-Q)	PU
03/08	Vertex: Q2 Earnings Snapshot	AQ
03/08	Vertex Reports Second Quarter 2026 Financial Results	BU
07/07	Vertex to Announce Second Quarter 2026 Financial Results on August 3rd	BU
07/07	Vertex Signs Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosis	AQ
06/07	Vertex to Acquire Crinetics Pharmaceuticals	BU
02/07	Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia	BU
11/06	Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions	BU
05/06	Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference	BU
03/06	Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10	BU
01/06	Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy	BU
11/05	Vertex to Participate in Upcoming May Investor Conferences	BU
07/05	Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany	AQ
06/05	Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany	BU
06/05	Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending MARCH 31, 2026 (Form 10-Q)	PU
04/05	Vertex Pharmaceuticals Incorporated : Q1 26 VRTX Earnings Presentation	PU
04/05	Vertex: Q1 Earnings Snapshot	AQ
04/05	Vertex Reports First Quarter 2026 Financial Results	BU
16/04	Vertex Pharmaceuticals Incorporated : 2025 Corporate Responsibility Report	PU
16/04	Vertex Pharmaceuticals Incorporated : 2025 Data Summary	PU
06/04	Vertex to Announce First Quarter 2026 Financial Results on May 4th	BU